Literature DB >> 12689737

Direct effect on validity of response run-in selection in clinical trials.

Vance W Berger1, Azadeh Rezvani, Vanessa A Makarewicz.   

Abstract

A run-in is a period prior to randomization during which potential participants who have met all entry criteria for a randomized clinical trial are assigned the same regimen, either the control (possibly placebo) or the experimental treatment. Typically, the intention is to exclude from the subsequent study (i.e., randomization) some segment of this cohort, based on their experiences during the run-in period. Selecting patients based on the run-in thereby forces differential representation of certain subpopulations relative to others. Previous studies have addressed the potential for a run-in to jeopardize validity through unintended mechanisms. While these concerns are valid, they leave open the possibility that modifications to the design of the run-in might be able to preserve validity, even if patient selection is based on the results of the run-in. As such, we address the potential for selecting patients based on response during a run-in period to jeopardize validity directly, through its intended effect of overrepresenting (relative to the screened population) some segments in the randomized portion of the trial and underrepresenting others.

Entities:  

Mesh:

Year:  2003        PMID: 12689737     DOI: 10.1016/s0197-2456(02)00316-1

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  12 in total

1.  Conflicts of Interest, Selective Inertia, and Research Malpractice in Randomized Clinical Trials: An Unholy Trinity.

Authors:  Vance W Berger
Journal:  Sci Eng Ethics       Date:  2014-08-24       Impact factor: 3.525

2.  CORR Insights ®: Have levels of evidence improved the quality of orthopaedic research?

Authors:  Vance W Berger
Journal:  Clin Orthop Relat Res       Date:  2013-08-01       Impact factor: 4.176

3.  Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Minjeong Park; Janet Williams; Diane Liu; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-07-09       Impact factor: 3.612

Review 4.  Association of run-in periods with weight loss in obesity randomized controlled trials.

Authors:  O Affuso; K A Kaiser; T L Carson; K H Ingram; M Schwiers; H Robertson; F Abbas; D B Allison
Journal:  Obes Rev       Date:  2013-09-30       Impact factor: 9.213

5.  Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) model.

Authors:  Anjali Gupta; Karen J Calfas; Simon J Marshall; Thomas N Robinson; Cheryl L Rock; Jeannie S Huang; Melanie Epstein-Corbin; Christina Servetas; Michael C Donohue; Gregory J Norman; Fredric Raab; Gina Merchant; James H Fowler; William G Griswold; B J Fogg; Kevin Patrick
Journal:  Contemp Clin Trials       Date:  2015-04-10       Impact factor: 2.226

Review 6.  Adaptive designs for randomized trials in public health.

Authors:  C Hendricks Brown; Thomas R Ten Have; Booil Jo; Getachew Dagne; Peter A Wyman; Bengt Muthén; Robert D Gibbons
Journal:  Annu Rev Public Health       Date:  2009       Impact factor: 21.981

7.  Biomedical research and corporate interests: a question of academic freedom.

Authors:  Leemon McHenry
Journal:  Mens Sana Monogr       Date:  2008-01

Review 8.  Placebo effect in clinical trial design for irritable bowel syndrome.

Authors:  Eric Shah; Mark Pimentel
Journal:  J Neurogastroenterol Motil       Date:  2014-04-30       Impact factor: 4.924

Review 9.  Study design considerations for irritable bowel syndrome clinical trials.

Authors:  Larry E Miller
Journal:  Ann Gastroenterol       Date:  2014

10.  Randomized controlled trials: who fails run-in?

Authors:  Judy R Rees; Leila A Mott; Elizabeth L Barry; John A Baron; Jane C Figueiredo; Douglas J Robertson; Robert S Bresalier; Janet L Peacock
Journal:  Trials       Date:  2016-07-29       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.